The determination of raloxifene in rat tissue using HPLC

Biomedical Chromatography

Volumn 21, Issue 3, 2007, Pages 229-233

  Yang, Zhaoyong ^a   He, Xiaobo ^a   Zhang, Yueqin ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Determination; HPLC; Raloxifene; Tissue

Indexed keywords

ACETONITRILE; BIOLOGICAL ORGANS; RATS;

DETERMINATION; HPLC; HPLC-UV; MOBILE PHASIS; RALOXIFENE; RAT TISSUE; REVERSED PHASE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TISSUE HOMOGENATES; VORTEX MIXING;

TISSUE;

ACETONITRILE; AMMONIUM ACETATE; METHANOL; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALIBRATION; CENTRIFUGATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; HEART; KIDNEY; LUNG; MALE; NONHUMAN; PRECIPITATION; QUANTITATIVE ANALYSIS; RAT; RELIABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; SINGLE DRUG DOSE; SPLEEN; TISSUE HOMOGENATE; ULTRAVIOLET SPECTROSCOPY;

RATTUS;

EID: 33947602699     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.725     Document Type: Article

References (13)

1. Blumenthal RS, Baranowski B and Dowsett SA. Cardiovascular effects of raloxifene: the arterial and venous systems. American Heart Journal 2004; 147: 783-789.
2. Chittacharoen A, Theppisai U and Manonai J. Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy. Climacteric 2002; 5:156-159.
3. Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL and Krege JH. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. Journal of Bone Mineral Research 2005; 20: 1905-1911.
4. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM and Eastell R. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. Journal of Clinical Endocrinology and Metabolism 2002; 87: 3609-3617.
5. Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R and Draper MW. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10: 337-344.
6. Karla C, Morello, Gregory T, Wurz, Michael W and DeGregorio. Pharmacokinetics of selective estrogen receptor modulators. Clinical Pharmacokinetics 2003; 42: 361-372.
7. Kemp DC, Fan PW and Stevens JC. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metabolism and Disposition 2002; 30: 694-700.
8. Lindstrom TD, Whitaker NG and Whitaker GW. Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica 1984; 14: 841-847.
9. Ni L, Allerheiligen SRB and Basson R. Pharmacokinetics of raloxifene in men and postmenopausal woman volunteers. (Abstract.) Pharmaceutical Research 1996; 13: S430.
10. Reginster JY and Devogelaer JP. Raloxifene reduces fractures in postmenopausal women with osteoporosis. Clinical and Orthopedic Related Research 2006; 443: 48-54.
11. Sporn MB, Dowsett SA, Mershon J and Bryant HU. Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action. Clinical Therapy 2004; 26: 830-840.
12. Trontelj J, Vovk T, Bogataj M and Mrhar A. HPLC analysis of raloxifene hydrochloride and its application to drug quality control studies. Pharmacology Research 2005; 52: 334-339.
13. Zhong DF. Several questions about establishing standard curve of biological assay with weighted least squares. Chinese Journal of Pharmoceutical Analysis 1996; 16: 343-347.